EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program
Oslo, Norway, 11 February 2026. Reference is made to the stock exchange announcement published 6 February 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), regarding the global investor call to be held in conjunction with the ongoing warrants exercise program.
As a reminder, the Company will host a global investor call (in English) today, Wednesday, 11 February 2026 at 3 PM CET / 9:00 AM EST. The presentation will be held by the Company’s CEO, Per Walday; CFO, John M. Edminson; and CBO, Caspar Foghsgaard. Please find attached a copy of the presentation that will be presented. The presentation will also be made available in the Investors section of the Company’s website.
To attend the webcast, please send an email to: ca@dnbcarnegie.no.
About EXACT Therapeutics EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX).
Further information may be found here: www.exact-tx.com
For further information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com